Shares of Indivior PLC (LON:INDV – Get Free Report) fell 19.6% during trading on Thursday . The company traded as low as GBX 548.71 ($6.93) and last traded at GBX 697.50 ($8.81). 2,765,005 shares were traded during mid-day trading, an increase of 277% from the average session volume of 733,828 shares. The stock had previously closed at GBX 868 ($10.97).
Analyst Upgrades and Downgrades
Separately, Jefferies Financial Group reissued a “buy” rating and issued a GBX 1,800 ($22.74) target price on shares of Indivior in a report on Tuesday, December 17th.
View Our Latest Research Report on INDV
Indivior Price Performance
Indivior Company Profile
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
See Also
- Five stocks we like better than Indivior
- Investing in Commodities: What Are They? How to Invest in Them
- DuPont’s Electronics Spinoff: The Start of Something Big
- What Investors Need to Know About Upcoming IPOs
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Market Shift: These 3 Stocks Are Winning While Big Tech Lags
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.
